Gilead Sciences 100% Cure Rate for HCV
From the title ” Hepatitis C Medicine Shows 100% Cure Rate”, you’d think the silver bullet has finally been found and there is no reason to look further. Is this serious competition with Abbott’s recent all oral treatment success? Maybe. But wait. The first sentence says “a small number of patients.” At this point, the Gilead trial only involves 25 patients and one had to drop out. I’ll say that’s small! The Abbot study involved almost 571 patients with a 99% cure rate.
Apparently there was hope earlier that Gilead and Bristol-Myers Squibb would combine their drugs, Sofosbuvir and Declatasvir respectively, after a trial of 44 genotype 2/3 patients and 44 genotype 1 patients showed an almost 100% cure rate. There was a small outcry that these two pharmaceuticals should hash out their differences so the world can be rid of HCV. But again, the original trial showing success was not all that big. By the numbers, I’ll pull for Abbott at this point in the competition. Am I missing something? What do you think?